Atomoxetine HCI

产品说明书

Print
Chemical Structure| 82248-59-7 同义名 : Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; Atomoxetine (hydrochloride); LY 139603 HCl; Atomoxetine HCl; LY 139603
CAS号 : 82248-59-7
货号 : A258704
分子式 : C17H22ClNO
纯度 : 98%
分子量 : 291.82
MDL号 : MFCD06410992
存储条件：

Pure form Inert atmosphere, store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(359.82 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(171.34 mM)，配合低频超声助溶
生物活性
靶点

  • 5-HT

    5-HT, Ki:77 nM
描述 Atomoxetine hydrochloride is a norepinephrine transporter (NET) inhibitor and also acts as an N-methyl-D-aspartate receptor (NMDAR) antagonist. In vivo, atomoxetine (3 mg/kg, intraperitoneal injection) seems to decrease glutamatergic transmission in a brain region-specific manner[3]. ICV (intracerebroventricularly) administration of atomoxetine at 200 – 250 nmol significantly reduced S-IRA (seizure-induced respiratory arrest) evoked by acoustic stimulation in DBA/1 mice. Peripheral atomoxetine administration at a dosage that reduces S-IRA (15 mg/kg, IP) slightly increased basal ventilation and the ventilatory response to 7% CO2[4].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00191880 Attention Deficit Hyperactivit... 展开 >>y Disorder 收起 << Phase 3 Completed - Canada ... 展开 >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Calgary, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Edmonton, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician London, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Montreal, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Saskatoon, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Scarborough, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician St. Johns, Canada For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Toronto, Canada 收起 <<
NCT00286949 Parkinson's Disease Not Applicable Completed - United States, Maryland ... 展开 >> Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 收起 <<
NCT00286949 - Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.43mL

0.69mL

0.34mL

17.13mL

3.43mL

1.71mL

34.27mL

6.85mL

3.43mL
参考文献

[1]Bymaster FP, Katner JS, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711.

[2]Zerbe RL, Rowe H, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther. 1985 Jan;232(1):139-43.

[3]Udvardi PT, Föhr KJ, Henes C, Liebau S, Dreyhaupt J, Boeckers TM, Ludolph AG. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study. Drug Des Devel Ther. 2013 Dec 4;7:1433-46.

[4]Zhao H, Cotten JF, Long X, Feng HJ. The effect of atomoxetine, a selective norepinephrine reuptake inhibitor, on respiratory arrest and cardiorespiratory function in the DBA/1 mouse model of SUDEP. Epilepsy Res. 2017 Nov;137:139-144.